Youxin Discloses Celnet Financials, No Immediate Thesis Change

What happened

Youxin Technology has published audited financials for Celnet and unaudited pro forma statements, detailing the financial impact of its October 2025 acquisition. This disclosure is part of the company's effort to showcase the Celnet deal, which is expected to add up to $1.3M in revenue for the first half of FY2026. Despite this transparency, the company remains in a precarious position with negative cash flow, Nasdaq compliance risks, and dilution from warrants. The DeepValue report emphasizes that the stock's future hinges on whether Celnet meets its revenue targets in the upcoming FY2026 1H results. Therefore, while the financials provide data, they do not alleviate the core uncertainties surrounding Youxin's ability to achieve operational stability.

Implication

The release of Celnet's financials offers a benchmark for future performance, but investors must remain cautious due to Youxin's history of financial distress and dilution. The pro forma statements hint at potential scale, but actual revenue conversion and cash burn reduction are critical. Upcoming earnings will be the true test, and any shortfall could exacerbate existing risks. Maintaining a wait stance is prudent until concrete progress is demonstrated. Ultimately, the investment thesis remains unchanged, pending operational evidence.

Thesis delta

The disclosure of Celnet's audited financials does not shift the investment thesis, as it merely provides historical data without altering the forward-looking expectations. However, it sets the stage for the crucial FY2026 1H results, which will determine if the revenue boost materializes. Investors should continue to monitor for Nasdaq compliance and dilution events as per the original thesis.